Gateley (Holdings)

AIM Rule 17 and Schedule 2(g) Disclosure

RNS Number : 5908M
Gateley (Holdings) PLC
22 September 2021

22 September 2021




("Gateley" or the "Group")


AIM Rule 17 and Schedule 2(g) Disclosure



Gateley (AIM: GTLY), the legal and professional services group, provides the following update pursuant to AIM Rule 17 and Schedule 2(g) (iii) to (viii) of the AIM Rules.


Nigel Payne, Non-Executive Chairman of the Group, was a director of Index Labs Limited ("Index Labs") from 1 May 2020 until 2 December 2020. On 2 August 2021, Index Labs was placed into administration. The most recently available filings indicate that the administration proceedings remain ongoing.



Gateley (Holdings) Plc

Neil Smith, Finance Director

Tel: +44 (0) 121 234 0196

Nick Smith, Acquisitions Director and Head of Investor Relations

Tel: +44 (0) 20 7653 1665

Cara Zachariou, Head of Corporate Communications

Tel: +44 (0) 121 234 0074 /

Mob: +44 (0) 7703 684 946

finnCap - Nominated adviser and broker

Tel: +44 (0) 20 7220 0575

Matt Goode / James Thompson/ Seamus Fricker  (Corporate Finance)

Andrew Burdis (ECM)

Singer Capital Markets - Joint broker

Tel: +44 (0) 20 7496 3000

Peter Steel (Corporate Finance)

Rachel Hayes (Corporate Broking)

Belvedere Communications Limited - Financial PR

Cat Valentine ([email protected])

Mob: +44 (0) 7715 769 078

Keeley Clarke ([email protected])

Mob: +44 (0) 7967 816 525

Llew Angus ([email protected])

Mob: +44 (0) 7407 023 147

[email protected]


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.